Gubra is the best YTD with +125% increase, Danish sector still in positive terrain YTD

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week the Danish healthcare stocks outperformed their Nordic counterparts. Acarix updated its business model in the U.S. and several companies presented new data including Acarix, IO Biotech, and Initiator Pharma. Finally, Curasight and Y-mAbs Therapeutics made changes to the board and management.

8 of the 21 Danish companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Gubra is now the best-performing Danish healthcare stock year-to-date with a 126% return and Biosergen was the best Nordic healthcare investment last week.

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.



Acarix announces the initiation of the first US-based clinical workflow evaluation study (Link)

Acarix adopts new growth-focused business model and provides outlook update as part of our ongoing strategic review (Link)

New Health Economic Analysis Presented at ACC Highlights The Acarix CADScor System’s Cost-Effectiveness (Link)

Ascendis Pharma

No news the past week


Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue (Link)


No news the past week

CS Medica

No news the past week


Curasight announces change in the Board of Directors (Link)

Evaxion Biotech

No news the past week


No news the past week


No news the past week


Transactions in Connection with Share Buy-back Program (Link)


No news the past week

Initiator Pharma

Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology (Link)

IO Biotech

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 (Link)

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week


No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer (Link)


No news the past week



On average, the Danish biotech and healthcare stocks delivered a negative share price performance of the past week of 0.4%. Biosergen rose 25% after they resolved a directed issue of 481,250 units. Acarix rose 3% in a very eventful week after new data were presented, a new business model introduced as well as initiation of their first US-based clinical workflow evaluation study. Curasight announced a change of chairman from Per Falholt to Kirsten Drejer. Finally, IO Biotech and Initiator Pharma also presented new data. The best stocks year-to-date continue to be Y-mAbs Therapeutics and Gubra with 111-126% increases after the first 3.5 months of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 2.4%.

Overview of share price developments the past week, year-to-date, and last twelve months


In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 0.4% to 60.66. The index was recovering from its all-time low in October of 57.12 but has since been on a downward trajectory. In the past 12 months, the index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 20%.

The index development for Kapital Partner Healthcare Index the past 12 months

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

36-58% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

Respiratorius AB (58%) is a research company focusing on the development of drug candidates for the treatment of cancer and especially aggressive lymphoma. The company was established in 1999 as a spin-off from Lund University.

Clincal Lasterthermia Systems AB (37%) vision is to develop and streamline the treatment of solid cancer tumors, where the company sells sterile patient kits. The products are used in various cancer treatments such as in the treatment of malignant melanoma, as well as lung, liver and pancreatic cancer. The stock rose following positive data.

Diagonal Bio AB (36%) is developing a platform called Panviral to detect and diagnose small sections of pathogen genomes, such as viruses, bacteria and fungi. In addition to the main business, the company also offers service and related ancillary services.

Sources: Refinitiv Eikon, Cision, Nordnet & company websites


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.